Sequent Scientific has witnessed a major ownership restructuring as CA Hull Investments acquired a substantial 31.20% stake through the composite scheme of amalgamation that became effective on December 16, 2025. The acquisition marks a significant milestone in the company's transformation following the completion of its amalgamation with Viyash Life Sciences and other entities.

Major Stake Acquisition Details

CA Hull Investments received 13,61,60,231 equity shares of Sequent Scientific through the share exchange mechanism established under the amalgamation scheme. The acquisition was executed based on the approved share exchange ratio and has resulted in CA Hull Investments becoming part of the promoter group, while CA Harbor Investments, acting as persons in concert, holds 30.20% stake.

The acquisition was completed through allotment pursuant to the composite scheme of amalgamation involving multiple entities including Viyash Life Sciences Private Limited, Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Geninn Life Sciences Private Limited, and Sequent Research Limited.

Capital Structure Transformation

The amalgamation scheme has significantly altered Sequent Scientific's capital structure, with the total equity share capital expanding substantially to accommodate the new shareholding pattern. Following the merger, CA Harbor Investments' shareholding was diluted from 52.33% pre-merger to 30.20% post-merger.

Regulatory Compliance and SEBI Disclosure

CA Hull Investments, based in Mauritius and operating through designated directors, has fulfilled all regulatory disclosure requirements under SEBI Takeover Regulations. The company filed the mandatory disclosure under Regulation 10(6) on December 17, 2025, one day after the share allotment completion. The acquisition is exempt from open offer obligations under Regulation 10(1)(d)(ii) of SEBI Takeover Regulations as it was executed through a tribunal-approved amalgamation scheme.

The acquisition represents a strategic consolidation within the pharmaceutical sector, with CA Hull Investments now holding significant influence in Sequent Scientific's operations and strategic direction. The transaction was executed without any encumbrances, pledges, or non-disposal undertakings, providing clear ownership rights to the acquiring entity. CA Hull Investments is represented by director Purnima Boyjonauth Bhogun and operates through Apex Fund Corporate Services (Mauritius) Ltd.

Sequent Scientific Limited , a prominent player in the pharmaceuticals sector, has taken another significant step to enhance employee engagement and ownership. The company's Nomination and Remuneration Committee has approved the allotment of 11,63,301 equity shares under its Employee Stock Option Plan 2020 (SeQuent ESOP 2020).

Latest Allotment Details

The committee approved the latest share allotment through a resolution passed by circulation, demonstrating the company's commitment to swift decision-making while adhering to corporate governance norms.

Updated Share Capital Structure

The allotment has resulted in a further increase in the company's paid-up equity share capital, building upon previous ESOP allotments:

Strategic Significance

This equity share allotment under the ESOP scheme continues to serve multiple strategic purposes for Sequent Scientific:

Employee Retention and Motivation: By offering stock options, the company aims to retain key talent and align employee interests with long-term organizational goals. The ESOP acts as a powerful incentive for employees to contribute to the company's growth and success.

Wealth Creation Opportunity: The scheme provides employees with an opportunity to benefit from the company's potential future growth and share price appreciation, fostering a culture of ownership.

Equity Rights and Compliance

The newly allotted shares will rank pari-passu with the existing equity shares of the company, ensuring equal rights in terms of voting and dividends as previously issued shares. This maintains equity among all shareholders while expanding the employee ownership base.

Market Position

As a mid-cap company in the pharmaceuticals sector with a market capitalization of ₹5,467.50 crores, Sequent Scientific continues to strengthen its position through strategic employee engagement initiatives. The company's focus on fostering shared success among its workforce reflects its commitment to sustainable growth in the competitive life sciences market.